{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:51:59Z","timestamp":1777521119741,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Psychiatry"],"published-print":{"date-parts":[[2003,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of administering quetiapine once vs twice daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Utilizing a double-blind design, 21 hospitalized adult men or women with DSM-IV schizophrenia or schizoaffective disorder, who had received unchanged doses (for 2 weeks) of either 400 or 600 mg daily of quetiapine administered in 2 doses, were randomly assigned to once- or twice-daily administration for 4 weeks and then crossed over to the opposite dosing regimen for an additional 4 weeks. Standard psychopathology and safety measures were used in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Nearly 70% (15\/21) of the subjects met the a priori efficacy responder criteria with no statistical differences in response between those assigned to once- or twice-daily quetiapine administration. Statistical analyses confirmed that most subjects maintained efficacy during the switch to once- or twice-daily administration with quetiapine. A minority (15%) did experience worsening of symptoms or orthostatic hypotension during the crossover. Quetiapine was generally well tolerated at either twice- or once-daily administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These pilot data suggest that it is clinically feasible to switch most quetiapine-treated subjects receiving a therapeutic twice-daily dosing schedule to a once-daily regimen. A minority may experience worsening of symptoms or orthostatic hypotension during the switch. This strategy of administering quetiapine entirely at bedtime may promote improved adherence to treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/070674370304800307","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T09:58:46Z","timestamp":1500544726000},"page":"187-194","source":"Crossref","is-referenced-by-count":24,"title":["A Random-Assignment, Double-Blind, Clinical Trial of Once- vs Twice-Daily Administration of Quetiapine Fumarate in Patients with Schizophrenia or Schizoaffective Disorder: A Pilot Study"],"prefix":"10.1177","volume":"48","author":[{"given":"KN Roy","family":"Chengappa","sequence":"first","affiliation":[{"name":"Staff Psychiatrist, Mayview State Hospital, Bridgeville, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haranath","family":"Parepally","sequence":"additional","affiliation":[{"name":"Staff Psychiatrist, Mayview State Hospital, Bridgeville, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaspreet S","family":"Brar","sequence":"additional","affiliation":[{"name":"Consulting Statistician, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Mullen","sequence":"additional","affiliation":[{"name":"Director, Clinical Research, AstraZeneca LP, Wilmington, Delaware"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Shilling","sequence":"additional","affiliation":[{"name":"Clinical Research Manager, AstraZeneca LP, Wilmington, Delaware"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Director, Clinical Science - CNS, AstraZeneca LP, Wilmington, Delaware"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,4,1]]},"reference":[{"key":"bibr1-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"bibr2-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830180067009"},{"key":"bibr3-070674370304800307","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140070-00003"},{"key":"bibr4-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050603"},{"key":"bibr5-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.3.360"},{"key":"bibr6-070674370304800307","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-IV","author":"American Psychiatric Association","year":"1994","edition":"4"},{"key":"bibr7-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"bibr8-070674370304800307","first-page":"217","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W.","year":"1976"},{"key":"bibr9-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"bibr10-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"bibr11-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"bibr12-070674370304800307","first-page":"534","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W.","year":"1976"},{"key":"bibr13-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290040080014"},{"key":"bibr14-070674370304800307","first-page":"337","volume":"26","author":"Chouinard G","year":"1990","journal-title":"Psychopharmacol Bull"},{"key":"bibr15-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(91)90050-2"},{"key":"bibr16-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(94)90116-3"},{"key":"bibr17-070674370304800307","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0906"},{"key":"bibr18-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.6.553"},{"key":"bibr19-070674370304800307","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820070032005"},{"key":"bibr20-070674370304800307","first-page":"247","volume":"49","author":"Tauscher-Wisniewski S","year":"2001","journal-title":"Schizophr Res"}],"container-title":["The Canadian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674370304800307","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674370304800307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:13:29Z","timestamp":1777392809000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/070674370304800307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1177\/070674370304800307"],"URL":"https:\/\/doi.org\/10.1177\/070674370304800307","relation":{},"ISSN":["0706-7437","1497-0015"],"issn-type":[{"value":"0706-7437","type":"print"},{"value":"1497-0015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}